Managing HIV lipoatrophy
- 1 February 2004
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 363 (9407), 412-414
- https://doi.org/10.1016/s0140-6736(04)15521-9
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazoneHepatology, 2003
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 2003
- Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapyAIDS, 2003
- Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic WomenDiabetes, 2002
- Effect of Recombinant Human Growth Hormone in the Treatment of Visceral Fat Accumulation in HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Abacavir Substitution for Nucleoside Analogs in Patients With HIV LipoatrophyA Randomized TrialJAMA, 2002
- Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophyJournal of Clinical Investigation, 2002
- Leptin-Replacement Therapy for LipodystrophyNew England Journal of Medicine, 2002
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998